Shifting the treatment model for resectable pancreatic cancer

Affiliations

Comment

Andrew H Ko. Lancet Gastroenterol Hepatol. 2018 Jun.

. 2018 Jun;3(6):375-376.

doi: 10.1016/S2468-1253(18)30094-3. Epub 2018 Apr 4.

¹ Division of Hematology and Oncology, University of California San Francisco, San Francisco, CA 94143, USA. Electronic address: andrew.ko@ucsf.edu.

No abstract available

Comment on

Safety and efficacy of preoperative or postoperative chemotherapy for resectable pancreatic adenocarcinoma (PACT-15): a randomised, open-label, phase 2-3 trial.
Reni M, Balzano G, Zanon S, Zerbi A, Rimassa L, Castoldi R, Pinelli D, Mosconi S, Doglioni C, Chiaravalli M, Pircher C, Arcidiacono PG, Torri V, Maggiora P, Ceraulo D, Falconi M, Gianni L. Reni M, et al. Lancet Gastroenterol Hepatol. 2018 Jun;3(6):413-423. doi: 10.1016/S2468-1253(18)30081-5. Epub 2018 Apr 4. Lancet Gastroenterol Hepatol. 2018. PMID: 29625841 Clinical Trial.